Previous 10 | Next 10 |
Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks’ lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Early Research and Development day highlight...
Zymeworks Inc. (NYSE:ZYME) could be one of the best biotech stocks to buy in November. The stock, which has crashed by 55.71% year-to-date, trades within narrow ranges, but the upside potential is growing. A brief technical outlook shows that ZYME has been within the same zone i...
Shares of clinical-stage biopharmaceutical company Zymeworks (NYSE: ZYME) rose 12.18% on Monday. The stock closed at $6.65 on Friday, opened on Monday at $6.69, and then ran to a high of $7.77 in the afternoon, before closing at $7.46. The stock has a 52-week low of $4.11 and a 52-w...
Summary Jazz Pharmaceuticals will pay $50 million upfront for an option to in-license Zymeworks' zanidatamab. Zymeworks carries most of the risk until Jazz opts in. If the deal goes through, Zymeworks would be in a great position to execute its development plan. The deal offer...
Summary Zymework's Jazz deal will bring $325mn in milestone payment if zanidatamab's BTC data is good. BTC data comes out by end 2022. That could be an important catalyst for this low-priced stock. I covered Canadian bispecific antibody drug developer Zymeworks ( Z...
SVB Securities downgraded Zymeworks Inc. ( NYSE: ZYME ) to Market Perform from Outperform on Friday, noting its recent pipeline updates and the licensing deal the Canadian biotech signed with Jazz Pharma ( JAZZ ) for cancer therapy zanidatamab. After discussions with...
Program beginning today at 8:30 AM Eastern Standard Time (EST) to feature updates and perspectives from Zymeworks senior leadership and scientific experts Progress in early-stage research designed to support Company goal to file up to five new Investigational New Drug (IND) ...
Shares of Zymeworks (NYSE: ZYME) were soaring 17% higher as of 10:54 a.m. ET on Wednesday. The big jump came after Zymeworks and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced an exclusive licensing deal for zanidatamab. Jazz will pick up development and marketing rights for ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Lissandra Melo / Shutterstock.com Generac (NYSE: GNRC ) stock is falling on Wednesday after the energy technology manufacturing company lowered its guidance for 2022 . Starting off that guidance cut i...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Zymeworks (NYSE: ZYME ) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ ). This agre...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...